SCHEMBL20249254

SCHEMBL20249254

CC(C)(C)c1ccc(N2CCNCCC2=O)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.40
PIM1 P11309 1/20 0.36
PIM3 Q86V86 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
CHRNB2 P17787 2/20 0.36
CHRNA4 P43681 2/20 0.36
TP53 P04637 2/20 0.36
AKR1C3 P42330 7/20 0.36
F10 P00742 1/20 0.36
ADRB1 P08588 1/20 0.34
HTT P42858 2/20 0.34
NPC1 O15118 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
LMNA P02545 2/20 0.34
GALR3 O60755 1/20 0.34
TSHR P16473 1/20 0.34
SLC6A2 P23975 1/20 0.34
CACNA2D1 P54289 1/20 0.34
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20255099 0.87 HTR6 (0.37) HTR6PIM1PIM3PIM2CHRNB2
SCHEMBL17207184 0.83 AKR1C3 (0.51) TP53AKR1C3HTTNPC1SMN1; SMN2
SCHEMBL17207179 0.82 AKR1C3 (0.50) TP53AKR1C3HTTNPC1SMN1; SMN2
SCHEMBL18291654 0.82 PIM1 (0.43) HTR6PIM1PIM3PIM2CHRNB2
SCHEMBL20249255 0.80 CYP1A2 (0.41) SMN1; SMN2TSHR
SCHEMBL5158426 0.80 HTR6 (0.43) HTR6PIM1PIM3PIM2CHRNB2
SCHEMBL20249262 0.80 SLC6A2 (0.51) HTR6CHRNB2CHRNA4TP53AKR1C3
SCHEMBL20037996 0.79 HTR6 (0.42) HTR6PIM1PIM3PIM2CHRNB2
SCHEMBL20203473 0.78 HTR6 (0.40) HTR6PIM1PIM3PIM2CHRNB2
SCHEMBL12145921 0.78 CHRNB2 (0.58) HTR6CHRNB2CHRNA4ADRB1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 HTR6 476/4885PIM1 596/4885PIM3 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.